While ‘data exclusivity’ clauses will not feature in the India-European Union free trade agreement (FTA), the threat posed by the impending deal to the world’s supply of cheap generic drugs is far from over. India’s commerce and industry minister Anand Sharma assured Michel Sidibe, chief of the United Nations joint programme on HIV and AIDS (UNAIDS) at a meeting this week that India would reject attempts by pharmaceutical giants to include...
More »SEARCH RESULT
Human Smears by Madhavi Tata
Poor Andhra villagers now victims of clinical drug trials No Drug Resistance * 35 women, some men from Guntur district put throughclinical trials of a breast cancer drug. They later complain of joint pains, nausea and chest pains. * Biotech industry in Andhra is worth about Rs 455 crore * Touts operating on behalf of pharma companies get people from the poorer districts to Hyderabad for the tests *** Some 35 women...
More »The Bitter Pills by Debarshi Dasgupta
India’s FTAs pip generic drugs production Lot More For Less * Generic drugs from India play a major role as antiretroviral drugs across the developing world * A 2010 study says 80% of the medicines used by donor-funded programmes to treat people with HIV were sourced from India * It’s cut down treatment costs drastically, from $10,000 to $80 * Stronger IP regimes may hamper production of generics *** The right of...
More »Rich Nations Wage Assault on Generic AIDS Drugs by Elizabeth Whitman
Moves by developed nations such as the United States to tighten intellectual property laws are threatening to limit production and distribution of generic drugs, which experts say have been and will remain key in the prevention and treatment of HIV/AIDS and currently account for 80 percent of HIV/AIDS treatment. These efforts are taking shape in two spheres. The first is in discussions on the outcome document that member states are expected...
More »Details of patented drugs to be made public by CH Unnikrishnan
To increase transparency, India’s patent regulator will soon make public details about patented drugs which include whether domestic demand for these medicines is met at a reasonable price. Patent holders in the country are required to submit once every year the so-called working details which include the quantity and value of a product that is sold, manufacturing base, quantity of production or imports, and a statement on whether public requirement has...
More »